Swedish Orphan Biovitrum AB

The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company’s commitments under the incentive programme

by

STOCKHOLM, June 20, 2023 /PRNewswire/ — The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 9 May 2023, resolved – for the purpose of ensuring that the company can fulfil its commitments under the long-term incentive programme for managers and executives (the Management Programme) resolved by the Annual General Meeting – on … Read more

Sobi to present new data at the 2023 EHA congress

by

STOCKHOLM, June 2, 2023 /PRNewswire/ — Sobi® will present data at the EHA (European Haematology Association) hybrid congress taking place in Frankfurt, Germany 8-11 June, 2023, highlighting the company’s commitment in rare haematological diseases. During the congress, Sobi will present important new data on haemophilia, immune thrombocytopenia, relapsed or refractory diffuse large b-cell lymphoma (DLBCL), and paroxysmal … Read more

Sobi commences tender offer for all outstanding shares of common stock of CTI BioPharma Corp.

by

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER OF OR THE SOLICITATION OF AN OFFER TO BUY SECURITIES IN ANY JURISDICTION. … Read more

EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

by

STOCKHOLM, May 19, 2023 /PRNewswire/ — Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for efanesoctocog alfa, a new class of high-sustained FVIII developed for the treatment of people with haemophilia A of all age groups. The application is based on data from the pivotal XTEND-1 … Read more

EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A

by

STOCKHOLM, May 19, 2023 /PRNewswire/ — Sobi today announced that the European Medicines Agency (EMA) has accepted and validated a marketing authorisation application for efanesoctocog alfa, a new class of high-sustained FVIII developed for the treatment of people with haemophilia A of all age groups. The application is based on data from the pivotal XTEND-1 … Read more